BU LABNET

A laboratory network and a new program model for external quality assessment of PCR based diagnostics for Buruli ulcer in endemic African countries














Summary of disease epidemiology

- 1. Buruli ulcer is a skin disease caused by *Mycobacterium ulcerans*
- 2. Cases have been reported from at least 33 countries
- 3. In 2018, 14/33 countries reported 2713 cases to WHO
- Most patients are children <15 yrs in Africa and adults >60 yrs in Australia
- 5. Mode of transmission is not known
- 6. Diagnosis is clinical + PCR
- 7. Treatment is a combination of rifampicin and clarithromycin for 8 weeks +/- skin grafting to speed up healing










The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. © WHO 2019. All rights reserved

Data Source: World Health Organization Map Production: Control of Neglected Tropical Diseases (NTD) World Health Organization









Background:


- Maintaining quality molecular diagnosis is a key to prevent and control the spread of Buruli ulcer in endemic African countries.
- Standardized and harmonized protocols for PCR based diagnosis of BU are essential to reduce ambiguity in the diagnostics methods and deliver quality results.
- A network that facilitates sharing of knowledge and best practices in diagnosing BU and conducting collaborative research can enhance the detection rates and contribute to reducing the global burden of the disease.

Objectives:

- To conduct external quality assessment program for diagnosis of BU through centralized coordinating system within the endemic countries.
- To establish standardized procedures for PCR-based diagnostics in BU considering the respective specific environment and available equipment
- To periodically monitor and provide necessary training to build the capacity of the member labs to conduct diagnosis with optimal quality.
- To represent the member labs under a network to enable knowledge sharing and conduct collaborative research to improve diagnostic approaches for BU.

Expected Outcomes/benefits:

- Harmonized testing procedures used by all the laboratories, which will ensure delivery of effective, efficient, accurate and reliable PCR Confirmation of Buruli ulcer in the African region
- Formalized functioning network of laboratories in the African region
- Improved and measurable performance of network labs on EQA testing
- Enhanced quality of data reported by WHO in Africa
- Publications obtained from collaborative research, which will enhance diagnostic approaches for BU
- Integrated NTDs in the PCR based platform for case confirmation in the different laboratories of the network



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data Source: WHO/UHC/NTD/IDM Map Production: WHO/UHC/NTD/IDM World Health Organization



Membership of the BU LAB NETWORK


Country	Laboratory	Contact persons
Benin	Laboratoire de Référence des Mycobactéries de Cotonou	Noudehouenou Senou Tel: +229 67 71 33 02; Email: claudeamarg@yahoo.fr
Benin	CDTUB, Pobé	Line-Marlène Ganlonon Tel: +229 95 94 88 99; Email: marleneganlonon@gmail.com
Cameroon	Centre Pasteur du Cameroun	Sara Eyangoh Tel: +237 699 777204; Email: eyangoh@pasteur-yaounde.org
Côte d'Ivoire	Institut Pasteur de Côte d'Ivoire	E. Solange Kakou-Ngazoa Tel: +225 08 24 04 53; Email:ngazoa_solange@yahoo.fr
DRC	Institut National de Recherche Biomédicale	Marie-Jose Kabedi Tel: +243 998 295 595; Email: bedye2001@yahoo.fr
Gabon	Centre International de Recherches Médicales de Franceville	Arsène Mabika-Mabika; +241 06 30 01 87; raaghmabika@gmail.com
Ghana	Kumasi Centre for Collaborative Research in Tropical Medicine	Richard Phillips Tel: +233 20 914 0451; Email: rodamephillips@gmail.com
Ghana	Noguchi Memorial Institute for Medical Research	Dorothy Yeboah-Manu Tel: +233 208123882; Email: DYeboah-Manu@noguchi.ug.edu.gh
Liberia	National Public Health Reference Laboratory	Vera Yatta Walker Tel: + 231 776421877; Email: yattawalker1@yahoo.com
Nigeria	Nigerian Institute of Medical Research	Olaoluwa Akinwale Tel: +234 8055146173; Email: pheabian@yahoo.co.uk
Togo	National Institute of Hygiène	Wemboo Afiwa Halatoko Tel:+ 228 90037378; Email: hjacky78@yahoo.fr

BU-LABNET members

The BU-LABNET comprises the following:


Core members: Laboratory experts from the network institutions performing PCR confirmation for Buruli ulcer in Africa

Associate members: Experts with interest in PCR for Buruli ulcer, other mycobacterial infections or skin-NTDs outside the core network



BU LABNET Resources/support **Coordination within countries** 1. Government Reference 2. Partners Laboratory **National** Health Programme facilities

Operational Framework – BU LABNET



- Coordination of the EQA
 Program
- Monitoring and evaluation of of member labs conducting BU diagnosis.
- Capacity building for PCR based diagnosis of BU
- Facilitate collaborative biomedical research to improve diagnostic approaches for BU.

NAG – Network Advisory Group


Organization and funding of the WHO BU - LABNET:


Coordination laboratory:

Pasteur Center of Cameroon

Funding:

- American Leprosy Missions (ALM)
- Foundation Raoul Follereau (FRF)
- WHO





BU-LABNET activities including impact of the COVID-19 crisis

The current COVID-19 outbreak has impacted the laboratory evaluation visits by the BU-LABNET experts that were initially planned for March and April 2020. Consequently, we will have to reschedule till further notice.

Also, procurement and shipment of reagents and consumables planned for April 2020 has been suspended till the end of the pandemic.

Other main activities from January 2020 including milestones

other main activities from January 2020 including innestones
☐ Recruitment of a program manager to coordinate network activities
☐ Successful harmonization of PCR testing protocols and dissemination to member labs
\square Strategic plan developed for 2020-2024; from the group SWOT analysis
☐ Document and communication shared point established
☐ BU-LABNET website development - ongoing
Ongoing development of standard operational procedures (SOPs) and other tools to facilitate implementation of the EQAP.
Drafted manuscript - describing the foundation work done in establishing this novel solid network of laboratories.

POST-COVID PLANS

After the COVID-19 outbreak, we plan to resume activities at full capacity, as follows:

- Re-launch purchase and shipment of PCR reagents and consumables for member labs - ongoing
- Finalize EQA procedures and start preparation of PT panels for shipment to member labs – ongoing
- ❖ Rapidly enhance network visibility; finalizing website and registration on other social media platforms accounts available on twitter, linkedin and facebook
- Re-schedule laboratory evaluation visits by network experts

BU-LABNET social media platforms

Twitter:

https://twitter.com/BU LabNet

Linkedin:

https://www.linkedin.com/company/buruli-ulcer-laboratory-network

Facebook:

https://www.facebook.com/Africabulabnet

Contact coordinating center

CENTRE PASTEUR DU CAMEROUN (CPC)

Laboratoire National de Référence et de Santé Publique, Cameroon

451, Rue 2005, Yaoundé 2

BP 1274 Yaoundé.

Telephone (Whatsapp): +237 674 517 255

+237 699 777 204

Email: <u>bu-labnet@pasteur-yaounde.org</u>

Website: http://www.africabulabnet.org/

